RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
44.45%
This Fund
S&P 500
1 Year Est. Return
+44.45%
AUM
$1.07B
AUM Growth
+$166M
(+18%)
Holding
105
Top Buys
| 1 | +$17.2M | |
| 2 | +$13.3M | |
| 3 | +$11.4M | |
| 4 |
Nuvalent
NUVL
|
+$10.9M |
| 5 |
Vera Therapeutics
VERA
|
+$10.3M |
Top Sells
| 1 | +$19M | |
| 2 | +$14.8M | |
| 3 | +$13.2M | |
| 4 |
Cytokinetics
CYTK
|
+$13.1M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$11.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biogen
BIIB
$27.7B
| $16.3M | 1.52% |
92,350
+37,350
|
|
||
27
Vertex Pharmaceuticals
VRTX
$127B
| $15.5M | 1.45% |
34,255
-12,700
|
|
||
28
Encompass Health
EHC
$10.7B
| $15.5M | 1.45% |
146,263
+26,863
|
|
||
29
Gilead Sciences
GILD
$184B
| $15.5M | 1.45% |
126,150
+46,000
|
|
||
30
Align Technology
ALGN
$12.1B
| $15.5M | 1.44% |
99,000
+16,000
|
|
||
31
Tenet Healthcare
THC
$20.6B
| $15.2M | 1.42% |
76,504
+18,075
|
|
||
32
BioMarin Pharmaceuticals
BMRN
$11.7B
| $12.8M | 1.19% |
215,000
+28,350
|
|
||
33
Jazz Pharmaceuticals
JAZZ
$11.4B
| $12.6M | 1.18% |
74,030
-21,000
|
|
||
|
34
Ionis Pharmaceuticals
IONS
$12.5B
| $12.5M | 1.17% |
158,500
-151,500
|
|
||
35
Amgen
AMGN
$202B
| $11.8M | 1.1% |
+36,000
|
|
||
36
LivaNova
LIVN
$3.39B
| $11.7M | 1.09% |
190,000
+137,000
|
|
||
37
Madrigal Pharmaceuticals
MDGL
$9.83B
| $11.4M | 1.06% |
19,550
+1,300
|
|
||
38
Cigna
CI
$69.2B
| $10.6M | 0.99% |
38,650
-7,850
|
|
||
39
Structure Therapeutics
GPCR
$4.12B
| $10.3M | 0.96% |
147,600
-32,500
|
|
||
40
Syndax Pharmaceuticals
SNDX
$2.13B
| $10.2M | 0.96% |
487,000
-87,000
|
|
||
41
Nurix Therapeutics
NRIX
$1.64B
| $10.2M | 0.95% |
537,500
+190,000
|
|
||
42
Pennant Group
PNTG
$1.18B
| $10.1M | 0.94% |
+357,346
|
|
||
43
Adaptive Biotechnologies
ADPT
$2.24B
| $9.83M | 0.92% |
605,000
+110,000
|
|
||
44
Penumbra
PEN
$13.2B
| $9.79M | 0.92% |
31,500
+11,000
|
|
||
45
Arrowhead Research
ARWR
$8.29B
| $9.59M | 0.9% |
+144,500
|
|
||
46
Apellis Pharmaceuticals
APLS
$2.51B
| $9.41M | 0.88% |
374,450
+142,200
|
|
||
47
Natera
NTRA
$28.2B
| $9.28M | 0.87% |
40,500
+9,500
|
|
||
48
Kura Oncology
KURA
$806M
| $9.06M | 0.85% |
872,000
+382,000
|
|
||
49
Arcellx
ACLX
$6.69B
| $8.7M | 0.81% |
133,500
+68,250
|
|
||
50
IDEAYA Biosciences
IDYA
$3.05B
| $8.64M | 0.81% |
+250,000
|
|